Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; an… Read more
Aelis Farma SA (AELIS) - Net Assets
Latest net assets as of June 2025: €6.11 Million EUR
Based on the latest financial reports, Aelis Farma SA (AELIS) has net assets worth €6.11 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€15.58 Million) and total liabilities (€9.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €6.11 Million |
| % of Total Assets | 39.25% |
| Annual Growth Rate | 29.21% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 802.88 |
Aelis Farma SA - Net Assets Trend (2017–2024)
This chart illustrates how Aelis Farma SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aelis Farma SA (2017–2024)
The table below shows the annual net assets of Aelis Farma SA from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €10.12 Million | -23.37% |
| 2023-12-31 | €13.20 Million | -33.29% |
| 2022-12-31 | €19.79 Million | +2103.79% |
| 2021-12-31 | €898.00K | +226.48% |
| 2020-12-31 | €-710.00K | -158.97% |
| 2019-12-31 | €1.20 Million | -49.52% |
| 2018-12-31 | €2.38 Million | +41.80% |
| 2017-12-31 | €1.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aelis Farma SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 27083400.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €32.00K | 0.32% |
| Common Stock | €137.00K | 1.35% |
| Other Comprehensive Income | €-12.40 Million | -122.62% |
| Other Components | €22.35 Million | 220.95% |
| Total Equity | €10.12 Million | 100.00% |
Aelis Farma SA Competitors by Market Cap
The table below lists competitors of Aelis Farma SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VVC Exploration Corporation
OTCQB:VVCVF
|
$5.01 Million |
|
Wolfden Resources Corporation
PINK:WLFFF
|
$5.01 Million |
|
Starteck Finance Limited
NSE:STARTECK
|
$5.01 Million |
|
UDAYSHIVAKUMAR INFRA ORD (BSE)
NSE:USK
|
$5.01 Million |
|
Precio Fishbone AB (publ)
ST:PRCO-B
|
$5.01 Million |
|
Turnstone Biologics Corp. Common Stock
NASDAQ:TSBX
|
$5.01 Million |
|
Sports Entertainment Group Ltd
AU:SEG
|
$5.01 Million |
|
Jaycorp Bhd
KLSE:7152
|
$5.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aelis Farma SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 13,201,000 to 10,116,000, a change of -3,085,000 (-23.4%).
- Net loss of 7,456,000 reduced equity.
- Share repurchases of 4,115,000 reduced equity.
- New share issuances of 4,527,000 increased equity.
- Other comprehensive income decreased equity by 2,207,000.
- Other factors increased equity by 6,166,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-7.46 Million | -73.71% |
| Share Repurchases | €4.12 Million | -40.68% |
| Share Issuances | €4.53 Million | +44.75% |
| Other Comprehensive Income | €-2.21 Million | -21.82% |
| Other Changes | €6.17 Million | +60.95% |
| Total Change | €- | -23.37% |
Book Value vs Market Value Analysis
This analysis compares Aelis Farma SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.69x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.13x to 1.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.18 | €1.25 | x |
| 2018-12-31 | €0.25 | €1.25 | x |
| 2019-12-31 | €0.13 | €1.25 | x |
| 2020-12-31 | €-0.07 | €1.25 | x |
| 2021-12-31 | €0.09 | €1.25 | x |
| 2022-12-31 | €1.67 | €1.25 | x |
| 2023-12-31 | €1.02 | €1.25 | x |
| 2024-12-31 | €0.74 | €1.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aelis Farma SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -73.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -278.42%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 1.95x
- Recent ROE (-73.71%) is below the historical average (-69.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -59.62% | -1173.24% | 0.01x | 3.74x | €-1.17 Million |
| 2018 | -114.51% | -6834.68% | 0.01x | 2.64x | €-2.97 Million |
| 2019 | -263.37% | -35826.46% | 0.00x | 6.00x | €-3.29 Million |
| 2020 | 0.00% | -183.47% | 0.16x | 0.00x | €-2.02 Million |
| 2021 | 63.85% | 6.33% | 0.32x | 31.49x | €484.10K |
| 2022 | -72.20% | -375.11% | 0.10x | 1.98x | €-16.27 Million |
| 2023 | -38.47% | -56.09% | 0.34x | 1.99x | €-6.40 Million |
| 2024 | -73.71% | -278.42% | 0.14x | 1.95x | €-8.47 Million |
Industry Comparison
This section compares Aelis Farma SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $12,563,915
- Average return on equity (ROE) among peers: -64.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aelis Farma SA (AELIS) | €6.11 Million | -59.62% | 1.55x | $5.01 Million |
| Abionyx Pharma SA (ABNX) | $8.89 Million | -56.01% | 1.06x | $72.33 Million |
| Abivax SA (ABVX) | $56.72 Million | -25.23% | 0.07x | $3.97 Billion |
| Adocia (ADOC) | $-6.91 Million | 0.00% | 0.00x | $84.57 Million |
| Acticor Biotech SAS (ALACT) | $-4.04 Million | 0.00% | 0.00x | $2.13 Million |
| NicOx S.A. (ALCOX) | $21.41 Million | -97.51% | 1.47x | $28.49 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $15.84 Million |
| ALGAE (ALGAE) | $32.76 Million | -39.31% | 0.56x | $29.13 Million |
| Genoway (ALGEN) | $5.23 Million | 9.60% | 1.10x | $23.45K |
| Integragen (ALINT) | $691.87K | -367.93% | 7.36x | $424.10K |